

1 Charles C. Weller (SBN: 207034)  
2 legal@cweller.com  
3 CHARLES C. WELLER, APC  
4 11412 Corley Court  
5 San Diego, California 92126  
6 Tel: 858.414.7465  
7 Fax: 858.300.5137

8 Attorney for Plaintiff Steven A. Cabrera

9  
10 **IN THE UNITED STATES DISTRICT COURT**  
11 **FOR THE SOUTHERN DISTRICT OF CALIFORNIA**  
12

13 STEVEN A. CABRERA, *individually and* )  
14 *on behalf of all those similarly situated,* )  
15 )  
16 *Plaintiff,* )

No. '25CV262 BEN VET

v. )

**CLASS ACTION COMPLAINT**

17 LAURA’S ORIGINAL BOSTON )  
18 BROWNIES, INC. dba BHU FOODS, a )  
19 *California corporation,* )  
20 )  
21 *Defendant.* )

JURY TRIAL DEMANDED

22  
23  
24  
25  
26  
27  
28  

Steven A. Cabrera (“Plaintiff”), individually and on behalf of all others similarly situated throughout the United States, by and through undersigned counsel, hereby brings this action against Laura’s Original Boston Brownies, Inc. dba Bhu Foods (“Bhu Foods” or “Defendant”), alleging that its Protein Cookies, double dark chocolate and chocolate chip flavors (“the Products”), which are manufactured, packaged, labeled, advertised, distributed, and sold by Defendant, are misbranded and falsely advertised because they feature deceptive protein claims on the front label and misrepresent the percent of Recommended Daily Value of protein contained in each serving, and upon information and belief and investigation of counsel alleges as follows:

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**PARTIES**

1. Plaintiff Steven A. Cabrera is and at all times relevant was a citizen of the state of Virginia, domiciled in Alexandria, Virginia.

2. Defendant Laura’s Original Boston Brownies, Inc. dba Bhu Foods is a California corporation with its principal place of business in San Diego, California. On information and belief all decisions regarding formulation and labeling of the Products are made at this principal place of business.

**JURISDICTION AND VENUE**

3. This Court has subject matter jurisdiction over this action pursuant to the Class Action Fairness Act, Pub. L. 109-2, 119 Stat. 4 (codified in scattered sections of Title 28 of the United States Code); specifically, under 28 U.S.C. § 1332(d), which provides for the original jurisdiction of the federal district courts over “any civil action in which the matter in controversy exceeds the sum or value of \$5,000,000, exclusive of interest and costs, and [that] is a class action in which . . . any member of a class of plaintiffs is a citizen of a State different from any defendant.” 28 U.S.C. § 1332(d)(2)(A).

4. Plaintiff seeks to represent Class members who are citizens of states different from the Defendant.

5. The matter in controversy in this case exceeds \$5,000,000 in the aggregate, exclusive of interests and costs.

6. In addition, “the number of members of all proposed plaintiff classes in the aggregate” is greater than 100. *See* 28 U.S.C. § 1332(d)(5)(B).

7. In the alternative, the Court has jurisdiction over this matter pursuant to 28 U.S.C. § 1332(a). The amount in controversy exceeds \$75,000, exclusive of interest and costs.

8. This Court has personal jurisdiction over Defendant because this action arises out of and relates to Defendant’s contacts with this forum.

9. Those contacts include but are not limited to sales of the Products directly to commercial and individual consumers located in this district, including Plaintiff; shipping the

1 Products to commercial and individual consumers in this district, including Plaintiff; knowingly  
2 directing advertising and marketing materials concerning the Products into this district through  
3 wires and mails, both directly and through electronic and print publications that are directed to  
4 commercial and individual consumers in this district; and operating an e-commerce web site  
5 that offers the Products for sale to commercial and individual consumers in this district, as well  
6 as offering the Products for sale through third-party e-commerce websites, through both of  
7 which commercial and individual consumers residing in this district have purchased the  
8 Products.

9 10. Defendant knowingly directs electronic activity and ships the Products into this  
10 district with the intent to engage in business interactions for profit, and it has in fact engaged in  
11 such interactions, including the sale of the Products to Plaintiff.

12 11. Defendant also sells the Products to retailers and wholesalers in this district for  
13 the purpose of making the Products available for purchase by individual consumers in this  
14 district.

15 12. Plaintiff's losses and those of other Class members were sustained in this district.

16 13. Venue is proper pursuant to 28 U.S.C. § 1391(b)(2) because a substantial part of  
17 the events or omissions giving rise to Plaintiff's claims occurred within this district.

18 14. Venue is also proper pursuant to 28 U.S.C. § 1391(c)(2) because this Court  
19 maintains personal jurisdiction over Defendant.

20 **FACTUAL ALLEGATIONS**

21 15. Millions of Americans consume specific amounts of protein in order to lose or  
22 maintain weight, build muscle, and meet fitness goals.<sup>1</sup> The past several decades have seen not  
23 only the rise of protein-centered diets such as the Atkins, paleo, or keto diets—which require  
24 adherents to carefully track “macros,” including protein—but also increased evidence that a  
25 protein-heavy diet can be critical to supporting muscle growth, making weight training more  
26

27 <sup>1</sup> See, e.g., Heather J. Leidy, “Increased Dietary Protein as a Dietary Strategy to Prevent and/or  
28 Treat Obesity,” *MO. MED.* (Jan./Feb. 2014), available at  
<https://pmc.ncbi.nlm.nih.gov/articles/PMC6179508/>.

1 efficient, and helping with weight loss and maintenance. In fact, “several clinical trials” have  
2 found that a high-protein diet “not only reduces body weight (BW), but also enhances body  
3 composition by decreasing fat mass while preserving fat-free mass (FFM),” more so than “both  
4 low-calorie and standard-calorie diets.”<sup>2</sup>

5 16. Central to the tracking of protein consumption is accurate nutritional labeling of  
6 foods and dietary supplements. As noted by U.S. Food and Drug Administration (“FDA”)   
7 Commissioner Margaret Hamburg during an October 2009 media briefing, “[s]tudies show that  
8 consumers trust and believe the nutrition facts information and that many consumers use it to  
9 help them build a healthy diet.” FDA recommends relying on Nutrition Facts panels on food  
10 labels as primary “tool for monitoring consumption of protein.”<sup>3</sup>

11 17. Plaintiff Steven A. Cabrera is one of those millions of Americans. He tracks his  
12 protein intake and consumes protein-fortified foods to ensure he gets enough protein in his diet.  
13 He does so in order to maintain his weight and meet fitness goals. As such, ensuring that he eats  
14 at least the Recommended Daily Value of protein—and more generally that he is able to  
15 accurately track his protein intake—is important to Mr. Cabrera.

16 18. As part of this effort and to assist in meeting his protein consumption goals,  
17 Plaintiff purchased the Products at a Whole Foods Market in Washington, D.C. on October 26,  
18 2024.

19 **A. Protein Quality and PDCAAS.**

20 19. Amino acids are the building blocks of proteins, whether that protein is derived  
21 from animals or plants. Both animal and plant proteins are composed of approximately 20 amino  
22 acids, which are essential for the synthesis of body proteins and other important nitrogen-  
23 containing compounds such as creatine, peptide hormones, and some neurotransmitters.

24  
25 \_\_\_\_\_  
26 <sup>2</sup> Jaecheol Moon & Gwanpyo Koh, “Clinical Evidence and Mechanisms of High-Protein Diet-  
Induced Weight Loss,” 29 J. OBESITY & METABOLIC SCI. 166-73 (2020), *available at*  
27 <https://pmc.ncbi.nlm.nih.gov/articles/PMC7539343/>.

28 <sup>3</sup> FDA, “Interactive Nutrition Fact Label – Protein,” *available at*  
[https://www.accessdata.fda.gov/scripts/InteractiveNutritionFactsLabel/assets/InteractiveNFL\\_Protein\\_October2021.pdf](https://www.accessdata.fda.gov/scripts/InteractiveNutritionFactsLabel/assets/InteractiveNFL_Protein_October2021.pdf).

1           20. There are nine amino acids that are not created by the human body: histidine,  
2 isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine, called  
3 “essential amino acids.” Human beings must consume these amino acids by digesting meat,  
4 animal products, plants, and other protein-rich foods that contain them.<sup>4</sup>

5           21. However, not all protein sources are created equally. Various protein sources  
6 contain all of the nine essential amino acids, while other protein types contain fewer of these  
7 amino acids. Thus, the *quantity* of protein by itself does not tell the full story of protein from a  
8 human nutritional standpoint. A protein’s *quality* is also critical because humans cannot fully  
9 digest or utilize some proteins, while other proteins are missing essential amino acids.

10           22. Protein sources that contain all or almost all of the essential amino acids are  
11 considered higher-quality proteins. These higher-quality proteins also tend to have a higher  
12 “bioavailability,” a term connoting the digestibility or the absorptive quality of a protein, *i.e.*,  
13 the ease with which the protein can be accessed and used by the human body in building muscle  
14 and undertaking other tasks.<sup>5</sup>

15           23. Scientists have developed a measure of protein quality called the Protein  
16 Digestibility Corrected Amino Acid Score, or PDCAAS.

17           24. The PDCAAS method combines a protein source’s amino acid profile and its  
18 percent digestibility into a discount factor ranging from 0.0 to 1.0 that, when multiplied by the  
19 total protein quantity, shows how much protein in a product is actually available to support  
20 human nutritional requirements.<sup>6</sup> The regulations term this the “corrected amount of protein per  
21 serving.” 21 C.F.R. § 101.9(c)(7)(ii).

22  
23  
24 <sup>4</sup> M.J. Lopez & S.S. Mohiuddin, “Biochemistry, Essential Amino Acids.” In StatPearls  
[Internet] (2025), available at <https://www.ncbi.nlm.nih.gov/books/NBK557845/>.

25 <sup>5</sup> See generally Claire Gaudichon & Juliane Calvez, “Determinants of amino acid  
26 bioavailability from ingested protein in relation to gut health.” 24 CURR. OP. CLIN. NUTR. &  
27 METABOLIC CARE 55 (2021), available at [https://pmc.ncbi.nlm.nih.gov/articles/  
PMC7752214/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7752214/); Stephan van Vliet, Nicholas Burd & Luc van Loon, “The Skeletal Muscle  
28 Anabolic Response to Plant- versus Animal-Based Protein Consumption.” 145 J. NUTR. 1981  
(2015), available at <https://pubmed.ncbi.nlm.nih.gov/26224750/>.

<sup>6</sup> Gertjan Schaafsma, “The protein digestibility-corrected amino acid score,” 130 J. NUTR.  
1865S-67S (2000), available at <https://pubmed.ncbi.nlm.nih.gov/10867064/>.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

25. Proteins have a range of PDCAAS. Animal-derived proteins such as cow’s milk, eggs, and whey have PDCAAS at or near 1.0. Soy also has a PDCAAS that is close to 1.0, while other plant-derived proteins have PDCAAS scores below 1.0—often much lower than 1.0—such as 0.7 for peas, 0.52 for peanuts, 0.5 for rice, and 0.42 for wheat.<sup>7</sup>

26. A PDCAAS of 1.0 signifies that the protein is a complete protein with optimal digestibility. A PDCAAS of 0.5 means that only half of the protein in that product is actually available to support human protein needs. If that product contained 10 grams total protein per serving, the “corrected” amount of protein in that product as described in 21 C.F.R. § 101.9(c)(7)(ii) would be only 5 grams per serving. Thus, protein products can vary widely in their ability to support human protein needs—even between two similar products with the same total amount of protein.

**B. PDCAAS and Food Labeling**

27. Because the PDCAAS method makes the differences in bioavailability among different types of proteins apparent to consumers, it has a critical role to play in nutritional labeling under relevant FDA regulations.

28. The FDA and other federal bodies set “Recommended Daily Values” for nutrients such as protein, which is the amount of that nutrient that the FDA recommends that a normal adult (or some other specified demographic) should consume every day to preserve their health and eat a balanced and nutrition diet. In the Nutrition Facts panel of foods (or the “Supplement Facts” panel of a dietary supplement), food manufacturers report the percentage of the Recommended Daily Value (“%DRV”) provided by a serving of the food or supplement. *See* FDA, “Daily Value on the Nutrition and Supplement Facts Labels,” *available at*

---

<sup>7</sup> *Id.* *See also* Joyce Boye, Ramani Wijesinha-Bettoni & Barbara Burlingame, “Protein quality evaluation twenty years after the introduction of the protein digestibility corrected amino acid score method,” 108 BR. J. NUTR. S183–S211 (2021), *available at* <https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/protein-quality-evaluation-twenty-years-after-the-introduction-of-the-protein-digestibility-corrected-amino-acid-score-method/51E5092761DA6004F1B081B204AAAB99>.

1 [https://www.fda.gov/food/nutrition-facts-label/daily-value-nutrition-and-supplement-facts-](https://www.fda.gov/food/nutrition-facts-label/daily-value-nutrition-and-supplement-facts-labels)  
2 [labels.](https://www.fda.gov/food/nutrition-facts-label/daily-value-nutrition-and-supplement-facts-labels)

3 29. FDA regulations state that if a Nutrition Facts or Supplement Facts panel  
4 expresses the protein content of a food in terms of %DRV, that disclosure must conform to and  
5 incorporate the PDCAAS method. That is, if reported, the %DRV must be “equal to the actual  
6 amount of protein (gram) per serving multiplied by the amino acid score corrected for protein  
7 digestibility,” which “shall be determined by methods given in sections 5.4.1, 7.2.1, and 8.00 in  
8 ‘Report of the Joint FAO/WHO Expert Consultation on Protein Quality Evaluation.’” 21 C.F.R.  
9 § 101.9(c)(7)(ii). *See also* Food Labeling: Nutrient Content Claims, General Principles,  
10 Petitions, Definition of Terms; Definitions of Nutrient Content Claims for the Fat, Fatty Acid,  
11 and Cholesterol Content of Food, 58 Fed. Reg. 2302, 2344 (Jan. 6, 1993) (when a nutritional  
12 label presents %DRV of protein it “must represent the corrected amount of protein based on its  
13 PDCAAS”).

14 30. These regulations are grounded in a recognition that 10 grams of pea or rice  
15 protein per serving does not offer the same %DRV of protein per serving as 10 grams of whey  
16 protein, because of whey protein’s 1.0 PDCAAS versus the much lower PDCAAS of pea and  
17 rice proteins. If the %DRV of a food containing such proteins is reported, it must be “corrected”  
18 by applying the PDCAAS of pea protein in the manner set forth in 21 C.F.R. § 101.9(c)(7)(ii).

19 31. There is a second instance in which manufacturers are required to report a  
20 PDCAAS-corrected %DRV in nutritional panels. Some foods or supplements make a “protein  
21 claim,” which is a claim outside of the Nutrition Facts or Supplement Facts panel that  
22 “characterize[s] the amount of protein in the products.” *Nacarino v. Kashi Company*, 77 F.4th  
23 1201, 1205 (9th Cir. 2023). These are often front label claims that a food contains “20 grams  
24 protein per serving,” or the like.

25 32. When a food makes a protein claim outside of the Nutrition Facts or Supplement  
26 Facts panel, the food manufacturer ***must*** disclose the PDCAAS-corrected %DRV in the panel.  
27 *See* 21 C.F.R. § 101.9(c)(7)(i). *See also Nacarino*, 77 F.4th at 1209 (“[I]f a product label includes  
28

1 a protein claim *outside* the [Nutrition Facts panel], section 101.9(c)(7)(i)'s trigger provision  
2 requires the manufacturer to also include the PDCAAS-corrected percent daily value *inside* the  
3 NFP") (emphases in original); 1211 ("The text and structure of the FDA regulations demonstrate  
4 that Defendants' protein claims could be misleading if ... the products did not display the  
5 quality-adjusted percent daily value in the NFP.").

6 33. FDA has stated in guidance to the public that "Food manufacturers may  
7 *voluntarily* list the %D[R]V of protein per serving on the Nutrition Facts label, but they are  
8 *required* to list the %D[R]V of protein if a statement is made on the package labeling about the  
9 health effects or the amount of protein (for example, 'high' or 'low') contained in the food."<sup>8</sup>

10 34. The reason for this requirement—that a food making a protein claim must display  
11 a PDCAAS-corrected %DRV in the Nutrition Facts panel—is to allow "consumers to readily  
12 identify foods of low protein quality." Food Labeling: Mandatory Status of Nutrition Labeling  
13 and Nutrient Content Revision, Format for Nutrition Label, 58 Fed. Reg. 2,079, 2,102 (1993).  
14 FDA's regulations recognize this requirement as "an important part of nutrition labeling." *Id.* at  
15 2,103.

16 35. The regulations set forth FDA's expert conclusion that (1) when manufacturers  
17 tout an amount of protein on the front label, that amount is likely to be material to the purchasing  
18 decisions of reasonable consumers, especially if the total amount of protein those consumers  
19 need to ingest on a daily basis to meet their Recommended Daily Value is not disclosed, and (2)  
20 not all proteins are the same in their ability to meet human nutritional requirements, so a simple  
21 statement about the number of grams does not actually inform consumers about how much  
22 usable protein they are receiving or how many servings they might need to consume meet their  
23 consumption goals.

24 36. Reporting of an accurate %DRV is especially important to the class of "protein-  
25 conscious consumers" who purchase protein-fortified products such as the Products, especially  
26

27 <sup>8</sup> FDA, "Interactive Nutrition Fact Label – Protein," *available at*  
28 [https://www.accessdata.fda.gov/scripts/InteractiveNutritionFactsLabel/assets/InteractiveNFL\\_Protein\\_October2021.pdf](https://www.accessdata.fda.gov/scripts/InteractiveNutritionFactsLabel/assets/InteractiveNFL_Protein_October2021.pdf) (emphases in original)



1 those who count protein macros or who otherwise track their protein intake. *Nacarino*, 77 F.4th  
2 at 1212.

3 37. Consumers rely on nutritional labeling to make informed decisions regarding the  
4 amount of a food or supplement they must consume to achieve their protein consumption goals,  
5 and to contextualize protein claims made on front label or otherwise outside of the nutritional  
6 panels.

7 38. A protein claim on a food or supplement is deceptive and misleading to consumers  
8 if it is not accompanied by a PDCAAS-corrected %DRV disclosure in the Nutrition Facts or  
9 Supplement Facts panel, because it gives reasonable consumers the impression that all of the  
10 protein in a product is high-quality protein that is bioavailable to consumers.

11 39. Bhu Foods makes a protein claim on the Products’ front label (or “principal  
12 display panel”) that the Products contain 11 or 12 grams of protein per serving:



27 40. The Products use pea protein as the sole protein source. The PDCAAS of such  
28 protein is significantly less than 1.0.

41. Because of the protein claim on the front label, Bhu Foods is required under 21 C.F.R. § 101.9(c)(7) to report a PDCAAS-corrected %DRV in the Nutrition Facts panel of the Products.

42. It does not. Instead, the Nutrition Facts panel on the Products states that the 11 or 12 grams of lower-quality protein in the Products provides 22 or 24 percent of the Recommended Daily Value, as shown here:



43. The protein claim on the principal display panel of the Products is deceptive and misleading to reasonable consumers because that claim is not clarified and contextualized by the disclosure of the quality-adjusted percent daily value in the Nutrition Facts panel.

1 **C. Plaintiff Reasonably Relied on Defendant’s Labelling Statements.**

2 44. Labels are the chief means by which food product manufacturers convey critical  
3 information to consumers, and consumers have been conditioned to rely on the accuracy of the  
4 claims made on these labels.

5 45. Consumers including Plaintiff especially rely on label claims made by food  
6 product manufacturers such as Defendant, as they cannot confirm or disprove those claims  
7 simply by viewing or even consuming the Products.

8 46. Further, federal law and corresponding state law and regulations both reflect and  
9 create reasonable consumer expectations concerning the contents of foods and beverages. That  
10 is, consumers have been conditioned to rely on the %DRV disclosures in a Nutrition Facts or  
11 Supplement Facts panel when determining how much of a food product they need to consume  
12 to obtain a specific amount of protein in their diet.

13 47. Plaintiff reviewed the front label and Nutrition Facts panel on the Products prior  
14 to his purchase, and reviewed the statements regarding protein being made in both places.  
15 Consumers such as Plaintiff who viewed the Products’ labels reasonably understood the  
16 Products to contain 11 or 12 grams of fully bioavailable, high-quality protein, comprising 22 or  
17 24 percent of the Recommended Daily Value of protein. This representation was false.

18 48. Consumers including Plaintiff reasonably relied on these label statements such  
19 that they would not have purchased the Products from Defendant if the truth about the Products  
20 was known, or would have only been willing to pay a substantially reduced price for the Products  
21 had they known that Defendant’s representations were false and misleading.

22 49. In the alternative, because of its deceptive and false labelling statements,  
23 Defendant was enabled to charge a premium for the Products relative to key competitors’  
24 products, or relative to the average price charged in the marketplace.

25 50. In addition to being unlawful under the FDA regulations cited herein, Defendant’s  
26 prominent protein claim on the front of the package, in the absence of any statement of the  
27 corrected amount of protein per serving expressed as a %DRV in the Nutrition Facts panel, is  
28



1 also likely to mislead reasonable consumers. Unless they are told otherwise, consumers  
2 reasonably expect that Defendant's Products will actually provide the full amount of  
3 bioavailable protein per serving claimed on the front of the package and stated in the protein  
4 quantity section of the Nutrition Facts panel, *i.e.*, that the Products contain high quality proteins.  
5 But Defendant's products do not. Instead, they consist of low-quality proteins that are not  
6 bioavailable.

7 51. Had Defendant included a statement of the corrected amount of protein per serving  
8 in the Nutrition Facts panel, as it was required to do under federal and state law, that disclosure  
9 would have revealed that less than half of the total protein quantity in the Products is useable by  
10 the human body, and that the Products contain low quality proteins.

11 52. That information was material to reasonable consumers, especially the class of  
12 protein-conscious consumers who are the target market of the Products. The absence of this  
13 information also allowed Defendant to charge a price premium to consumers including Plaintiff.

14 53. Plaintiff suffered economic injury by Defendant's fraudulent and deceptive  
15 conduct as stated herein, and there is a causal nexus between Defendant's deceptive conduct and  
16 Plaintiff's injury.

17 **CLASS ACTION ALLEGATIONS**

18 54. Plaintiff brings this action individually and as representative of all those similarly  
19 situated pursuant to Federal Rule of Civil Procedure 23 on behalf of all consumers in the state  
20 of California who purchased the Products within four years prior to the filing of this Complaint.

21 55. Excluded from the Class are Defendant and its affiliates, parents, subsidiaries,  
22 employees, officers, agents, and directors. Also excluded are any judicial officers presiding over  
23 this matter and the members of their immediate families and judicial staff.

24 56. Plaintiff reserves the right to alter the Class definition, and to amend this  
25 Complaint to add additional Subclasses, as necessary to the full extent permitted by applicable  
26 law.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

57. Certification of Plaintiff’s claims for class-wide treatment is appropriate because Plaintiff can prove the elements of the claims on a class-wide basis using the same evidence as individual Class members would use to prove those elements in individual actions alleging the same claims.

58. **Numerosity – Rule 23(a)(1):** The size of the Class is so large that joinder of all Class members is impracticable. Plaintiff believes and avers there are thousands of Class members geographically dispersed throughout the state of California.

59. **Existence and Predominance of Common Questions of Law and Fact – Rule 23(a)(2), (b)(3):** There are questions of law and fact common to the Class. These questions predominate over any questions that affect only individual Class members. Common legal and factual questions and issues include but are not limited to:

- a. Whether the marketing, advertising, packaging, labeling, and other promotional materials for Defendant’s Products is misleading and deceptive;
- b. Whether a reasonable consumer would understand Defendant’s protein claim to indicate that the Products contain 11 or 12 grams of fully bioavailable high-quality protein and provide a specific percentage of the Daily Recommended Value of protein, and reasonably relied upon those representations;
- c. Whether Defendant was unjustly enriched at the expense of the Plaintiff and Class members;
- d. Whether Defendant breached an express warranty;
- e. the proper amount of damages;
- f. the proper scope of injunctive relief; and
- g. the proper amount of attorneys’ fees.

60. Defendant engaged in a common course of conduct in contravention of the laws Plaintiff seeks to enforce individually and on behalf of the Class. Similar or identical violations of law, business practices, and injuries are involved. Individual questions, if any, pale by comparison, in both quality and quantity, to the numerous common questions that predominate

1 this action. The common questions will yield common answers that will substantially advance  
2 the resolution of the case.

3 61. In short, these common questions of fact and law predominate over questions that  
4 affect only individual Class members.

5 62. **Typicality – Rule 23(a)(3):** Plaintiff’s claims are typical of the claims of the Class  
6 members because they are based on the same underlying facts, events, and circumstances  
7 relating to Defendant’s conduct.

8 63. Specifically, all Class members, including Plaintiff, were harmed in the same way  
9 due to Defendant’s uniform misconduct described herein; all Class members suffered similar  
10 economic injury due to Defendant’s misrepresentations; and Plaintiff seeks the same relief as  
11 the Class members.

12 64. There are no defenses available to Defendant that are unique to the named  
13 Plaintiff.

14 65. **Adequacy of Representation – Rule 23(a)(4):** Plaintiff is a fair and adequate  
15 representative of the Class because Plaintiff’s interests do not conflict with the Class members’  
16 interests. Plaintiff will prosecute this action vigorously and is highly motivated to seek redress  
17 against Defendant.

18 66. Furthermore, Plaintiff has selected competent counsel who are experienced in  
19 class action and other complex litigation. Plaintiff and Plaintiff’s counsel are committed to  
20 prosecuting this action vigorously on behalf of the Class and have the resources to do so.

21 67. **Superiority – Rule 23(b)(3):** The class action mechanism is superior to other  
22 available means for the fair and efficient adjudication of this controversy for at least the  
23 following reasons:

- 24 a. the damages individual Class members suffered are small compared to the burden  
25 and expense of individual prosecution of the complex and extensive litigation  
26 needed to address Defendant’s conduct such that it would be virtually impossible  
27 for the Class members individually to redress the wrongs done to them. In fact,  
28

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

they would have little incentive to do so given the amount of damage each member has suffered when weighed against the costs and burdens of litigation;

- b. the class procedure presents fewer management difficulties than individual litigation and provides the benefits of single adjudication, economies of scale, and supervision by a single Court;
- c. the prosecution of separate actions by individual Class members would create a risk of inconsistent or varying adjudications, which would establish incompatible standards of conduct for Defendant; and
- d. the prosecution of separate actions by individual Class members would create a risk of adjudications with respect to them that would be dispositive of the interests of other Class members or would substantively impair or impede their ability to protect their interests.

68. Unless the Class is certified, Defendant will retain monies received as a result of its unlawful and deceptive conduct alleged herein.

69. Unless a class-wide injunction is issued, Defendant will likely continue to advertise, market, promote, and sell its Products in an unlawful and misleading manner, as described throughout this Complaint, and members of the Class will continue to be misled, harmed, and denied their rights under the law. Defendant continues to mislabel the Products in the manner described herein and sell them to the consuming public. Defendant would like to purchase the Products and other products sold by Defendant in the future, but cannot currently do so because he cannot rely on the Products' labelling, given the deceptions regarding protein quality found there. An injunction prohibiting future deceptive labelling is therefore warranted and would provide Plaintiff and the Class relief.

70. Furthermore, Plaintiff has not merely alleged an "informational" injury, but has also alleged that Defendant has been enabled to charge a price premium for the Products. Plaintiff has therefore alleged that compliance with federal and state regulations regarding the accurate reporting of protein content and quality in the Products would cause a decrease in the

1 price of the Products at which Plaintiff and members of the Class would be willing to buy the  
2 Products. As a result, Plaintiff has alleged more than simply an interest in Defendant telling the  
3 truth on its labels, but an economic injury that further supports prospective injunctive relief.

4 71. **Ascertainability.** To the extent ascertainability is required, the Class members are  
5 readily ascertainable from Defendant’s records and/or its agents’ records of retail and online  
6 sales, as well as through public notice.

7 72. Defendant has acted on grounds applicable to the Class as a whole, thereby  
8 making appropriate final injunctive and declaratory relief concerning the Class as a whole.

9  
10 **COUNT 1**  
11 **VIOLATION OF THE CONSUMER LEGAL REMEDIES ACT,**  
12 **CAL. CIV. CODE § 1750 *et seq.***

13 73. Plaintiff realleges the preceding paragraphs as if fully set forth herein and, to the  
14 extent necessary, pleads this cause of action in the alternative.

15 74. Plaintiff is a “consumer” within the meaning of the Consumer Legal Remedies  
16 Act (“CLRA”), Cal. Civ. Code § 1761(d).

17 75. The sale of Defendant’s Products to Plaintiff and Class members was a  
18 “transaction” within the meaning of the CLRA, Cal. Civ. Code § 1761(e).

19 76. The Products purchased by Plaintiff and Class members are “goods” within the  
20 meaning of the CLRA, Cal. Civ. Code § 1761(a).

21 77. As alleged herein, Defendant’s business practices are a violation of the CLRA  
22 because Defendant deceptively failed to reveal facts that are material in light of the protein  
23 claims that were made by Defendant on the principal display panel of its Products.

24 78. Defendant’s ongoing failure to provide material facts about its Products on its  
25 labels violates the following subsections of Cal. Civ. Code § 1770(a) in these respects:

- 26 a. Defendant’s acts and practices constitute misrepresentations that its Products have  
27 characteristics, benefits, or uses which they do not have;
- 28 b. Defendant misrepresented that its Products are of a particular standard, quality,  
and/or grade, when they are of another;



- c. Defendant’s acts and practices constitute the advertisement of goods, without the intent to sell them as advertised;
- d. Defendant’s acts and practices fail to represent that transactions involving its Products involve actions that are prohibited by law, particularly the use of misleading nutritional labelling; and
- e. Defendant’s acts and practices constitute representations that its Products have been supplied in accordance with previous representations when they were not.

79. By reason of the foregoing, Plaintiff and the Class have been irreparably harmed, entitling them to injunctive relief.

80. Pursuant to Cal. Civ. Code § 1782, Plaintiff notified Defendant in writing of the particular violations of the CLRA described herein and demanded Defendant rectify the actions described above by providing complete monetary relief, agreeing to be bound by their legal obligations and to give notice to all affected customers of their intent to do so. Plaintiff sent this notice by certified mail to Defendant, at least 30 days before the filing of this Complaint.

81. Pursuant to Cal. Civ. Code §§ 1770 and 1780, Plaintiff and the Class are entitled to recover actual damages sustained as a result of Defendant’s violations of the CLRA. Such damages include, without limitation, monetary losses and actual, punitive, and consequential damages, in an amount to be proven at trial.

82. Pursuant to Cal. Civ. Code §§ 1770 and 1780, Plaintiff is entitled to enjoin publication of misleading and deceptive nutritional labels on Defendant’s Products and to recover reasonable attorneys’ fees and costs.

**COUNT 2  
UNJUST ENRICHMENT**

83. Plaintiff realleges the preceding paragraphs as if fully set forth herein and, to the extent necessary, pleads this cause of action in the alternative in the event that Plaintiff has an inadequate remedy at law.

84. Under California law, a claim for unjust enrichment “describe[s] the theory underlying a claim that a defendant has been unjustly conferred a benefit ‘through mistake,

1 fraud, coercion, or request.” *Astiana v. Hain Celestial Grp., Inc.* (9th Cir. 2015) 783 F.3d 753,  
2 762 (quoting *55 Cal. Jur. 3d Restitution* § 2). Thus, when a plaintiff alleges unjust enrichment,  
3 the Court should “construe the cause of action as a quasi-contract claim seeking restitution.”  
4 *Rutherford Holdings, LLC v. Plaza Del Rey* (2014) 223 Cal.App.4th 221, 225. Courts in  
5 California have allowed unjust enrichment and CLRA claims to proceed in the alternative. *See*  
6 *Scheibe v. Livwell Prods., LLC*, No. 23-cv-216, 2023 WL 4414580, at \*8 (S.D. Cal. 2023).

7 85. Defendant, through its marketing and labeling of the Products, misrepresented and  
8 deceived consumers by misrepresenting that the Products provided 11 or 12 grams of fully  
9 bioavailable protein that constituted 22 or 24 percent the Recommended Daily Value of protein.

10 86. Defendant did so for the purpose of enriching itself and it in fact enriched itself  
11 by doing so.

12 87. Consumers conferred a benefit on Defendant by purchasing the Products,  
13 including an effective premium above their true value. Defendant appreciated, accepted, and  
14 retained the benefit to the detriment of consumers.

15 88. Defendant continues to possess monies paid by consumers to which Defendant is  
16 not entitled.

17 89. Under the circumstances it would be inequitable for Defendant to retain the benefit  
18 conferred upon it and Defendant’s retention of the benefit violates fundamental principles of  
19 justice, equity, and good conscience.

20 90. Plaintiff seeks disgorgement of Defendant’s ill-gotten gains and restitution of  
21 Defendant’s wrongful profits, revenue, and benefits, to the extent, and in the amount, deemed  
22 appropriate by the Court, and such other relief as the Court deems just and proper to remedy  
23 Defendant’s unjust enrichment.

24 91. Plaintiff has standing to pursue this claim as Plaintiff has suffered injury in fact as  
25 a result of Defendant’s actions as set forth above.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

**COUNT 3  
BREACH OF EXPRESS WARRANTY**

92. Plaintiff realleges the preceding paragraphs as if fully set forth herein and, to the extent necessary, pleads this cause of action in the alternative.

93. Defendant, as the designer, manufacturer, marketer, distributor, and/or seller, expressly warranted that the Products contained 11 or 12 grams of fully bioavailable protein that constituted 22 or 24 percent of the Recommended Daily Value of protein.

94. Defendant’s express warranties, and its affirmations of fact and promises made to Plaintiff and the Class and regarding the Products, became part of the basis of the bargain between Defendant and Plaintiff and the Class, which creates an express warranty that the Products would conform to those affirmations of fact, representations, promises, and descriptions.

95. The Products do not conform to the express warranty that the Products contain 11 or 12 grams of fully bioavailable protein because they contain a lower-quality protein with a PDCAAS of less than 1.0.

96. As a direct and proximate cause of Defendant’s breach of express warranty, Plaintiff and Class members have been injured and harmed because: (a) they would not have purchased the Products on the same terms if they knew the truth about the Products’ protein claim; (b) they paid a price premium based on Defendant’s express warranties; and (c) the Products do not have the characteristics, uses, or benefits that were promised.

**PRAYER FOR RELIEF**

WHEREFORE, Plaintiff respectfully requests the Court grant the following relief against Defendant:

- a. Certifying the Class;
- b. Declaring that Defendant violated the CLRA and/or was unjustly enriched and/or breached an express warranty;
- c. Awarding actual and other damages as permitted by law;

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

- d. Ordering an awarding of injunctive relief as permitted by law, including enjoining Defendant from continuing the unlawful practices as set forth herein, and ordering Defendant to engage in a corrective advertising campaign;
- e. Ordering Defendant to pay reasonable attorneys’ fees and litigation costs to Plaintiff;
- f. Ordering Defendant to pay both pre- and post-judgment interest on any amounts awarded; and
- g. Such other relief as the Court may deem just and proper.

TRIAL BY JURY IS DEMANDED ON ANY COUNTS SO TRIABLE.

Respectfully submitted,

/s/ Charles C. Weller  
Charles C. Weller (Cal. SBN: 207034)  
Attorney for Plaintiff

February 5, 2025

CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)

I. (a) PLAINTIFFS

STEVEN A. CABRERA, individually and on behalf of all those similarly situated

(b) County of Residence of First Listed Plaintiff Fairfax, VA (EXCEPT IN U.S. PLAINTIFF CASES)

(c) Attorneys (Firm Name, Address, and Telephone Number)

Charles C. Weller, CHARLES C. WELLER APC, 11412 Corley Ct., San Diego CA 92126 858.414.7465

DEFENDANTS

LAURA'S ORIGINAL BOSTON BROWNIES, INC. dba BHU FOODS, a California corporation

County of Residence of First Listed Defendant San Diego (IN U.S. PLAINTIFF CASES ONLY)

NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF THE TRACT OF LAND INVOLVED.

Attorneys (If Known)

'25CV262 BEN VET

II. BASIS OF JURISDICTION (Place an "X" in One Box Only)

- 1 U.S. Government Plaintiff, 2 U.S. Government Defendant, 3 Federal Question (U.S. Government Not a Party), 4 Diversity (Indicate Citizenship of Parties in Item III)

III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff and One Box for Defendant)

- Citizen of This State, Citizen of Another State, Citizen or Subject of a Foreign Country, PTF DEF, 1 1, 2 2, 3 3, 4 4, 5 5, 6 6

IV. NATURE OF SUIT (Place an "X" in One Box Only)

Click here for: Nature of Suit Code Descriptions.

Table with columns: CONTRACT, REAL PROPERTY, CIVIL RIGHTS, TORTS, PRISONER PETITIONS, FORFEITURE/PENALTY, LABOR, IMMIGRATION, BANKRUPTCY, SOCIAL SECURITY, FEDERAL TAX SUITS, OTHER STATUTES. Includes various legal categories like Personal Injury, Property Damage, Labor, Intellectual Property Rights, etc.

V. ORIGIN (Place an "X" in One Box Only)

- 1 Original Proceeding, 2 Removed from State Court, 3 Remanded from Appellate Court, 4 Reinstated or Reopened, 5 Transferred from Another District, 6 Multidistrict Litigation - Transfer, 8 Multidistrict Litigation - Direct File

VI. CAUSE OF ACTION

Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity): 28 U.S.C. section 1332. Brief description of cause: Consumer fraud action for deceptively labeled products

VII. REQUESTED IN COMPLAINT:

CHECK IF THIS IS A CLASS ACTION UNDER RULE 23, F.R.Cv.P. DEMAND \$ 5,000,000. CHECK YES only if demanded in complaint: JURY DEMAND: Yes No

VIII. RELATED CASE(S) IF ANY

(See instructions): JUDGE DOCKET NUMBER

DATE 2/5/2025 SIGNATURE OF ATTORNEY OF RECORD /s/ Charles C. Weller

FOR OFFICE USE ONLY

RECEIPT # AMOUNT APPLYING IFP JUDGE MAG. JUDGE